Market capitalization | $7.49b |
Enterprise Value | $6.68b |
P/E (TTM) P/E ratio | 22.47 |
EV/FCF (TTM) EV/FCF | 24.07 |
EV/Sales (TTM) EV/Sales | 3.32 |
P/S ratio (TTM) P/S ratio | 3.72 |
P/B ratio (TTM) P/B ratio | 3.53 |
Revenue growth (TTM) Revenue growth | 17.48% |
Revenue (TTM) Revenue | $2.01b |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
23 Analysts have issued a Exelixis, Inc. forecast:
23 Analysts have issued a Exelixis, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 2,014 2,014 |
17%
17%
|
|
Gross Profit | 1,935 1,935 |
17%
17%
|
|
EBITDA | 429 429 |
124%
124%
|
EBIT (Operating Income) EBIT | 403 403 |
185%
185%
|
Net Profit | 350 350 |
113%
113%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
Head office | United States |
CEO | Michael Morrissey |
Employees | 1,310 |
Founded | 1994 |
Website | www.exelixis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.